Does lower testosterone in women cause reduced sexual desire and arousal?

The association between testosterone levels and sexual function in women is a complex relationship where clinical efficacy and biochemical markers often diverge. For a postmenopausal individual, the evidence suggests that while testosterone plays a critical role in sexual health, the absolute concentration in the blood is rarely a reliable predictor of symptoms.

Clinical effectiveness and observational findings

Research consistently demonstrates that testosterone is effective for treating sexual dysfunction, even when baseline levels are within "normal" ranges.

• A comprehensive meta-analysis of 36 randomized controlled trials (8,480 postmenopausal women) found that testosterone therapy significantly increased the frequency of satisfying sexual encounters (mean difference 0.85 per month) and improved sexual desire, arousal, and self-image while reducing sexual distress.
• Despite these therapeutic benefits, large-scale cross-sectional studies (such as those involving thousands of women) consistently fail to find a statistically significant correlation (p > 0.05) between endogenous serum total or free testosterone levels and scores on validated sexual function scales like the Female Sexual Function Index (FSFI).
• Because of this lack of correlation, there are no established "low" testosterone thresholds to diagnose sexual dysfunction in women; the diagnosis remains clinical, based on symptoms of Hypoactive Sexual Desire Disorder (HSDD).

Mechanistic explanations

The biological influence of testosterone on sexual function is mediated through both central and peripheral pathways:

• Central mechanisms: Androgen receptors are concentrated in the hypothalamus and limbic system. Testosterone modulates dopamine release in the medial preoptic area, a key region for sexual motivation and "wanting."
• Peripheral mechanisms: In genital tissues, testosterone maintains the structural integrity of vaginal and clitoral tissue and regulates blood flow and lubrication via the nitric oxide-cyclic GMP pathway, directly impacting physiological arousal.
• Intracellular action: The lack of correlation with serum levels is often attributed to local intracrinology, where peripheral tissues convert precursors like DHEA into active androgens locally, making circulating levels a poor proxy for tissue-specific androgenic activity.

Bottom line

The claim is plausible because testosterone therapy effectively restores desire and arousal in postmenopausal women with HSDD. However, it is not supported as a direct linear association; circulating testosterone levels do not accurately reflect sexual function or predict who will benefit from treatment.